These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 30586714

  • 21. Crosstalk between BMP signaling and KCNK3 in phenotypic switching of pulmonary vascular smooth muscle cells.
    Yeo Y, Jeong H, Kim M, Choi Y, Kim KL, Suh W.
    BMB Rep; 2022 Nov; 55(11):565-570. PubMed ID: 36016502
    [Abstract] [Full Text] [Related]

  • 22. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
    Happé C, Kurakula K, Sun XQ, da Silva Goncalves Bos D, Rol N, Guignabert C, Tu L, Schalij I, Wiesmeijer KC, Tura-Ceide O, Vonk Noordegraaf A, de Man FS, Bogaard HJ, Goumans MJ.
    Cells; 2020 Jun 08; 9(6):. PubMed ID: 32521690
    [Abstract] [Full Text] [Related]

  • 23. Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.
    Fessel JP, Flynn CR, Robinson LJ, Penner NL, Gladson S, Kang CJ, Wasserman DH, Hemnes AR, West JD.
    Am J Respir Cell Mol Biol; 2013 Nov 08; 49(5):778-87. PubMed ID: 23742019
    [Abstract] [Full Text] [Related]

  • 24. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G, Wang X, Li Y, He L.
    Stem Cell Res Ther; 2017 Feb 10; 8(1):34. PubMed ID: 28187784
    [Abstract] [Full Text] [Related]

  • 25. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
    Zakrzewicz A, Hecker M, Marsh LM, Kwapiszewska G, Nejman B, Long L, Seeger W, Schermuly RT, Morrell NW, Morty RE, Eickelberg O.
    Circulation; 2007 Jun 12; 115(23):2957-68. PubMed ID: 17515463
    [Abstract] [Full Text] [Related]

  • 26. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
    Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, Loscalzo J, Zhang YY.
    Am J Physiol Heart Circ Physiol; 2008 Aug 12; 295(2):H677-90. PubMed ID: 18552156
    [Abstract] [Full Text] [Related]

  • 27. MiR-23a regulates the proliferation and migration of human pulmonary artery smooth muscle cells (HPASMCs) through targeting BMPR2/Smad1 signaling.
    Zhang Y, Peng B, Han Y.
    Biomed Pharmacother; 2018 Jul 12; 103():1279-1286. PubMed ID: 29864909
    [Abstract] [Full Text] [Related]

  • 28. BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.
    Harper RL, Reynolds AM, Bonder CS, Reynolds PN.
    Respirology; 2016 May 12; 21(4):727-33. PubMed ID: 26809239
    [Abstract] [Full Text] [Related]

  • 29. Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.
    West JD, Carrier EJ, Bloodworth NC, Schroer AK, Chen P, Ryzhova LM, Gladson S, Shay S, Hutcheson JD, Merryman WD.
    PLoS One; 2016 May 12; 11(2):e0148657. PubMed ID: 26863209
    [Abstract] [Full Text] [Related]

  • 30. 17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.
    Frump AL, Albrecht M, Yakubov B, Breuils-Bonnet S, Nadeau V, Tremblay E, Potus F, Omura J, Cook T, Fisher A, Rodriguez B, Brown RD, Stenmark KR, Rubinstein CD, Krentz K, Tabima DM, Li R, Sun X, Chesler NC, Provencher S, Bonnet S, Lahm T.
    J Clin Invest; 2021 Mar 15; 131(6):. PubMed ID: 33497359
    [Abstract] [Full Text] [Related]

  • 31. Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle.
    van der Bruggen CE, Happé CM, Dorfmüller P, Trip P, Spruijt OA, Rol N, Hoevenaars FP, Houweling AC, Girerd B, Marcus JT, Mercier O, Humbert M, Handoko ML, van der Velden J, Vonk Noordegraaf A, Bogaard HJ, Goumans MJ, de Man FS.
    Circulation; 2016 May 03; 133(18):1747-60. PubMed ID: 26984938
    [Abstract] [Full Text] [Related]

  • 32. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension.
    McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Michelakis ED, Archer SL.
    Am J Physiol Lung Cell Mol Physiol; 2007 Apr 03; 292(4):L872-8. PubMed ID: 17142350
    [Abstract] [Full Text] [Related]

  • 33. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.
    Li M, Vattulainen S, Aho J, Orcholski M, Rojas V, Yuan K, Helenius M, Taimen P, Myllykangas S, De Jesus Perez V, Koskenvuo JW, Alastalo TP.
    Am J Respir Cell Mol Biol; 2014 Jun 03; 50(6):1118-28. PubMed ID: 24433082
    [Abstract] [Full Text] [Related]

  • 34. The Impact of Heterozygous KCNK3 Mutations Associated With Pulmonary Arterial Hypertension on Channel Function and Pharmacological Recovery.
    Bohnen MS, Roman-Campos D, Terrenoire C, Jnani J, Sampson KJ, Chung WK, Kass RS.
    J Am Heart Assoc; 2017 Sep 09; 6(9):. PubMed ID: 28889099
    [Abstract] [Full Text] [Related]

  • 35. Impaired Interleukin-15 Signaling via BMPR2 Loss Drives Natural Killer Cell Deficiency and Pulmonary Hypertension.
    Hilton LR, Rätsep MT, VandenBroek MM, Jafri S, Laverty KJ, Mitchell M, Theilmann AL, Smart JA, Hawke LG, Moore SD, Renaud SJ, Soares MJ, Morrell NW, Ormiston ML.
    Hypertension; 2022 Nov 09; 79(11):2493-2504. PubMed ID: 36043416
    [Abstract] [Full Text] [Related]

  • 36. Deep phenotyping of unaffected carriers of pathogenic BMPR2 variants screened for pulmonary arterial hypertension.
    Tóth EN, Celant LR, Niglas M, Jansen S, Tramper J, Baxan N, Ashek A, Wessels JN, Marcus JT, Meijboom LJ, Houweling AC, Nossent EJ, Aman J, Grynblat J, Perros F, Montani D, Vonk Noordegraaf A, Zhao L, de Man FS, Bogaard HJ.
    Eur Respir J; 2024 Oct 09; 64(4):. PubMed ID: 38991711
    [Abstract] [Full Text] [Related]

  • 37. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2.
    Girerd B, Coulet F, Jaïs X, Eyries M, Van Der Bruggen C, De Man F, Houweling A, Dorfmüller P, Savale L, Sitbon O, Vonk-Noordegraaf A, Soubrier F, Simonneau G, Humbert M, Montani D.
    Chest; 2015 May 09; 147(5):1385-1394. PubMed ID: 25429696
    [Abstract] [Full Text] [Related]

  • 38. Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.
    Talati MH, Brittain EL, Fessel JP, Penner N, Atkinson J, Funke M, Grueter C, Jerome WG, Freeman M, Newman JH, West J, Hemnes AR.
    Am J Respir Crit Care Med; 2016 Sep 15; 194(6):719-28. PubMed ID: 27077479
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The genetic basis of pulmonary arterial hypertension.
    Ma L, Chung WK.
    Hum Genet; 2014 May 15; 133(5):471-9. PubMed ID: 24442418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.